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Abstract
Background: We and others have previously reported that resveratrol (RSV) suppresses colon cancer cell
proliferation and elevates apoptosis in vitro and/or in vivo, however molecular mechanisms are not fully elucidated.
Particularly, little information is available on RSV’s effects on metabolic pathways and the cell-extra cellular matrix
(ECM) communication that are critical for cancer cell growth. To identify important targets of RSV, we analyzed
whole protein fractions from HT-29 advanced human colon cancer cell line treated with solvent control, IGF-1 (10
nM) and RSV (150 μM) using LC/MS/MS-Mud PIT (Multidimensional Protein Identification Technology).
Results: Pentose phosphate pathway (PPP), a vital metabolic pathway for cell cycle progression, was elevated and
suppressed by IGF-1 and RSV, respectively in the HT-29 cell line. Enzymatic assays confirmed RSV suppression of
glucose-6 phosphate dehydrogenase (rate limiting) and transketolase, key enzymes of the PPP. RSV (150 μM)
suppressed, whereas IGF-1 (10 nM) elevated focal adhesion complex (FAC) proteins, talin and pFAK, critical for the
cell-ECM communication. Western blotting analyses confirmed the suppression or elevation of these proteins in
HT-29 cancer cells treated with RSV or IGF-1, respectively.
Conclusions: Proteomic analysis enabled us to establish PPP and the talin-pFAK as targets of RSV which suppress
cancer cell proliferation and induce apoptosis in the colon cancer cell line HT-29. RSV (150 μM) suppressed these
pathways in the presence and absence of IGF-1, suggesting its role as a chemo-preventive agent even in obese
condition.
Keywords: Resveratrol, Proteomics, Talin, Focal Adhesion Kinase (FAK), Pentose Phosphate Pathway, Insulin-like
Growth Factor-1 (IGF-1)
Background
Cancer is a multifactorial disease whereas cancer cells
can upregulate multiple defense mechanisms to evade
drug treatments and therapies. It is therefore important
to study the different mechanisms of compounds show-
ing promise in chemopreventive efficacy to further
enhance targeted therapy development. Proteomic analy-
sis, a powerful method for discovery of new biomarkers
and pathways, has recently been used in studies of
obesity, diabetes, and especially cancer [1-3]. Proteomic
profiling not only offers a method to study cancer but
has also indeed broadened our understanding of multi-
ple cancers. Nowadays, profiling and discovery of novel
biomarkers are required for not only diagnosis but also
for accurate understanding of mechanisms and causes of
metabolic disorders [2].
Resveratrol (RSV, 3,5,4’-trihydroxy-trans-stilbene), a
stilbenoid and a potent chemopreventive bioactive com-
pound, is found in the skin of red grapes, and peanuts.
RSV exerts anti-cancer properties by inhibiting three
major stages of carcinogenesis, namely tumor initiation,
promotion and progression [4]. RSV has been studied
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extensively as a chemopreventive/anti-proliferative agent
in multiple cancer types including colon and prostate
cancers [5,6]. We reported previously that RSV sup-
pressed colon cancer cell proliferation and induced
apoptosis even in the presence of IGF-1, a well-known
growth factor elevated during obesity which has shown
to enrich colon cancer stem cell populations [6,7]. RSV
targets p53 and IGF-1R/Wnt signaling pathways to sup-
press colon cancer cell proliferation and induce apopto-
sis. RSV interactions with p53, Akt and other effector
proteins that regulate proliferation and apoptosis are
well documented [6,8-13]. However, the effects of RSV
on metabolic pathways like the pentose phosphate path-
way (PPP) and the cell-extracellular matrix (ECM) pro-
tein interaction, important in cancer cell growth and
proliferation are not clearly understood.
High concentrations of RSV used in this study and
other studies on colon cancer cell lines are quite achiev-
able in the colon (luminal- as epithelial cells are exposed
to RSV directly) with novel pectin based formulations,
as most of the trans-resveratrol reaches the colon unal-
tered. The pectin formulation protects RSV from upper
GI tract enzymes and allows for targeted release in the
colon (i.e., colon-specific drug delivery system). Pectin
(biopolymer) used in such formulations is safe for oral
intake and almost completely degraded by colonic bac-
teria [14-16]. Moreover, studies with human subjects
revealed that resveratrol is well tolerated even at high
oral doses (daily intake of up to 5 g) without adverse
effects [17-19]. Juan et al [20] suggested that wines with
14.3 mg/L RSV could provide a luminal concentration
of around 80 μM of trans resveratrol. Thus, novel for-
mulations that protect RSV from first-pass metabolism
or presystemic metabolism during GI transit and with
RSV being safely tolerated in high doses, it is quite pos-
sible to achieve 100-150 μM RSV in the colon. Thus,
use of dietary bioactive compounds at pharmacological
doses, is emerging as a therapeutic approach to target
colon cancer in humans.
Over-activation of the IGF system is frequently
observed in obese conditions and plays a key role in
obesity-promoted colon cancer [21]. Activation of the
IGF system due to elevated circulating levels of IGF-1
stimulates colonocyte proliferation [21-24]. IGF-1 bound
to IGF-1R activates downstream signaling pathways to
promote proliferation and cell cycle progression [25,26].
We have previously shown that RSV suppressed IGF-1
signaling via suppression of IGF-1R resulting in G1 cell
cycle arrest and suppression of proliferation in HT-29
and SW480 colon cancer cells [6].
The metabolic pentose phosphate pathway (PPP) pro-
duces ribose-5-phosphate required for the synthesis of
nucleotides. Cell proliferation requires metabolic sources
for the duplication of DNA and cell size [27]. Therefore,
PPP is frequently up-regulated in cancer cells; especially
in HT-29 cells where, it has been shown that the PPP is
very important for cell cycle progression [28]. This path-
way is divided into two branches. The oxidative branch
uses glucose-6-phosphate as a substrate to generate
NADPH, NADPH acts as a reducing agent for the main-
tenance of reduced glutathione levels and fatty acid
synthesis. On the other hand, the non-oxidative branch
recycles pentose phosphates to glycolytic intermediates
and generates de novo ribose-5-phosphate for nucleotide
biosynthesis. Key regulatory enzymes of PPP are glu-
cose-6-phosphate dehydrogenase (G6PDH) rate limiting
enzyme in the oxidative branch and transketolase (TKT)
in the non-oxidative branch [28,29].
Cell-cell and cell-ECM interactions are important for
viability and cell growth. Cell adhesion and migration
contribute to normal processes such as differentiation,
embryonic development, and wound healing. However,
in cancer cells such processes are also significant for
invasion and metastasis [30]. Key mechanistic steps in
these processes involve the extracellular protein interac-
tion with cell specific adhesive receptors such as integ-
rins [31]. In cancer cells, these interactions serve as a
link between extracellular and intracellular signals and
regulate cell adhesion leading to invasion, proliferation,
anoikis (anchorage independent apoptosis), survival and
tumor progression [32]. Even though interruption of
cell-ECM adhesion is a potential strategy for cancer pre-
vention and treatment, and in spite of the cell-ECM
components frequently modulated in chemoprevention
studies, not much is known about the potential effects
of the bioactive compounds like RSV on cell-ECM and
integrin dynamics [33]. Talin is an integrin regulatory
protein that translates the external message into regula-
tory intracellular signal transduction cascades. Cell-ECM
interactions mediated via integrin/talin convey vital
information to the cell interior to regulate cell prolifera-
tion and differentiation [34]. Focal adhesion kinase
(FAK) is another member in the family of molecules
that regulates cell adhesion dynamics, stimulates multi-
ple cellular signal transduction events leading to cell
motility, proliferation and survival [35,36]. Talin has also
been suggested to mediate FAK activation upon integrin
stimulation [34]. FAK and IGF-1R have been shown to
activate common pathways, leading to increased cell
proliferation and survival. These studies suggest that
talin-FAK signaling plays an important role in signaling
initiated by integrins that translates into downstream
signaling pathways [34].
In the present study, we used the power of functional
proteomics to unravel critical components of the cancer
chemoprevention ability of RSV in HT-29 advanced
human colon cancer cells. The whole protein fraction of
RSV (150 μM) or IGF-1 (10 nM) treated HT-29 cells
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was analyzed using LC/MS/MS. IGF-1 elevated and RSV
suppressed G6PDH and TKT, the 2 key enzymes of oxi-
dative and non-oxidative branches of the PPP, respec-
tively, indicating that RSV suppressed cell cycle
progression of HT-29 cells by down-regulating the PPP.
Proteins in the focal adhesion complex were also found
to be differentially regulated by RSV and IGF-1. RSV
(150 μM) suppressed the talin and phosphorylated Fak
protein levels even in the presence of IGF-1, a potent
mitogen, indicating that RSV anti-cancer effects against
human colon cancer cell might be partly due to disrup-
tion of cell-ECM interaction. On the basis of these
results, we found the PPP and the talin-FAK signaling
as critical targets of RSV.
Results
Proteomic Analysis of HT-29 colon cancer cells treated
with RSV and IGF-1
HT-29 cells were treated with either DMSO (solvent
control), IGF-1 (10 nM) or RSV (150 μM). LC/MS/MS-
Mud PIT analysis of HT-29 cells detected 1231 proteins
among all three treatment groups. Using quantile nor-
malization technique allowed us to scale all protein
abundances in all samples to the same distribution. This
allows realistic estimation of fold change between
experimental conditions (Additional File 1, Figure S1).
The list of identified proteins and respective normalized
fold changes were imported into GeneGo Metacore soft-
ware to analyze cellular processes significantly altered by
IGF-1 and RSV with respect to control. Fifty most dif-
ferentially represented biological pathways were identi-
fied in the set of proteins across all experimental
conditions and are presented in Figure S2 (Additional
file 2, Figure S2). Major pathways affected by RSV and
IGF-1 include those responsible for cytoskeleton remo-
deling, apoptosis signaling, cell cycle, cell adhesion,
inflammation and glucose metabolism (top 10 pathways
presented in Figure 1). Pathways that had p < 0.05 were
considered significant. RSV responsive pathways, the
PPP and the cytoskeleton remodeling pathway, which
play a critical role in cancer cell kinetics, were chosen to
determine if RSV suppression of proliferation and
induction of apoptosis involves suppression of metabolic
pathways such as the PPP and disruption of cell-ECM
crosstalk.
IGF-1 and RSV modulate the PPP to target cell cycle
progression in human colon cancer cell line HT29
PPP is frequently up-regulated in cancer cells. Proteomic
analysis revealed that G6PDH and TKT the two key
enzymes of the oxidative and non-oxidative branches of
the PPP respectively, were altered by RSV or IGF-1
treatment. We observed that RSV attenuated G6PDH
and TKT levels (Figure 2). Results using enzyme kinetic
assays for both G6PDH and TKT support these observa-
tions. RSV (100-150 μM) suppressed and IGF-1 elevated
both G6PDH and TKT levels. Even in the presence of
IGF-1, RSV suppressed G6PDH and TKT enzymatic
levels confirming its efficacy in obese conditions (Figure
3A and 3B). Potentiated G6PDH and TKT suppression
by RSV (150 μM) in the presence of IGF-1 may be due
to up-regulation of reactive oxygen species by both IGF-
1 and RSV at high concentration leading to elevated
apoptosis [6,37-39].
RSV suppresses while IGF-1 elevates the talin-Fak
signaling pathway
Proteomic analysis revealed that the cytoskeleton remo-
deling pathway is one of the critical pathways (4th)
altered in the HT-29 colon cancer cells treated with
RSV or IGF-1 (Figure 1). As cytoskeletal components
make up a major portion of total protein in most tis-
sues, it is not surprising to see quantitative changes in
this category of proteins. One of the major signaling
pathways in the cytoskeleton remodeling, is the interac-
tion between proteins talin and FAK. Both RSV and
IGF-1 altered the talin-FAK signaling pathway, but the
differences were not significant (Figure 4). However,
activation of talin-FAK signaling and up-regulation of
phosphorylated FAK levels have been observed in variety
of cancer cells [34,36,40-43]. The levels of talin and
pFAK were measured using western blots. Confirmatory
results using western blot demonstrated that IGF-1
Figure 1 First 10 most differentially represented biological
pathways identified in the set of proteins across all
experimental conditions. The complete list of top 50 statistically
significant pathways is given in Additional file 2, Figure S2.
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elevated and RSV (150 μM) suppressed talin and phos-
phorylated (activated) FAK levels (Figure 5). At lower
concentrations RSV increased the talin expression but at
higher concentration suppressed the talin expression.
This may be due to differential activity of RSV at low vs
high concentration-anti-oxidant at low concentration
and pro-oxidant at high [38,44]. At all concentrations
RSV suppressed IGF-1 induced talin and pFAK levels
(Figure 5) confirming efficacy of RSV in the presence of
IGF-1.
Discussion
The modern-day approach to cancer management is
multidisciplinary, consisting of surgery, radiation therapy
and chemotherapy with potential side effects. Several
investigations are underway to improve the efficacy of
these treatment modalities or to find new ways to treat
or prevent cancer. Proteomics technology plays an
important role in finding and validating biomarkers for
cancer. Bioactive compounds like RSV have multiple
mechanisms of action. It is vital to discover novel tar-
gets/biomarkers of chemopreventive agents like RSV
that has multiple mechanisms of action so that those
targets could be harnessed to develop targeted therapies.
The goal of the study was to identify RSV target pro-
teins and mechanisms implicated in its anti-neoplastic
activities. The use of the proteomics technology enabled
us to identify an array of proteins modulated by RSV.
Although our present analysis accessed a small window
in the cellular proteome, it was possible to detect RSV
modulation of 1231 proteins in the HT-29 cell line. To
determine if the expression of many of these proteomic
Figure 2 Map of pentose phosphate pathway (Genego Metacore) overlapped with quantile-normalized estimations of protein
abundance. Flags indicate direction of change (red, up-increased, blue; down-decreased) and fold change (length) of protein abundance in
relation to solvent control. 1, IGF-1 and 2, Resveratrol. Results were expressed as mean for three replicate experiments for each treatment group.
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markers was modified at both low and high concentra-
tions of RSV, our confirmatory analysis included wes-
tern blots and enzyme kinetic assays using RSV at
concentrations 50-150 μM alone or after pre incubation
with IGF-1, a mitogen elevated during obesity.
We have previously reported that at concentrations >
100 μM RSV suppressed colon cancer proliferation and
up-regulated apoptosis even in the presence of IGF-1,
elevated during obesity, and that has shown to enrich
colon cancer stem cell populations [6,7]. Apoptotic
levels correlated with pp53 levels and suppression of
proliferation transpired via attenuation of IGF-1R/Akt/
Wnt signaling pathways. The present study focuses on
novel targets of RSV that govern the proliferation, apop-
tosis and growth of a cancer cell. Using the pathway
analysis software the important targets from the pool of
proteins differentially altered by IGF-1 or RSV treatment
were selected to devise pathways that have not been
studied.
Genego Metacore software provided a basis to eval-
uate pathways based on differentially expressed pro-
teins. As expected major canonical pathways affected
were from the actin cytoskeleton signaling, oxidative
stress response pathways, glucose metabolism, apopto-
sis and cell cycle etc. Among the significantly
expressed proteins, G6PDH and TKT from the pen-
tose phosphate pathway family and talin and FAK
from the cytoskeleton family were found to be differ-
entially expressed in RSV or IGF-1 treatments (Figure
1, 2 and 4). This along with the data showing that the
glycolytic pathways [45,46] and the cell-ECM interac-
tion [1] to be frequently deregulated in cancer cells,
fueled interest in RSV, the PPP and the talin-pFAK
interaction.
Cell division is an energy-demanding process and its
correct progression depends on sufficient metabolic
resources to support a doubling of cell mass. Though
nutrient availability is a key factor for cell proliferation,
nucleotide synthesis is a rate limiting step in cancer cell
replication [29]. Ribose-5-phosphate, which is a key
nucleotide component, is synthesized from glycolytic
intermediates in the PPP. PPP is considered important
in tumor proliferation processes because of its role in
supplying tumor cells with reduced NADP and carbons
for intracellular anabolic processes [27]. In particular,
the two key enzymes G6PDH and TKT have been
shown to play a critical role in cancer cell cycle progres-
sion in the HT-29 cell line [28,29].
In this study, we have demonstrated, using two differ-
ent experimental approaches, that the PPP which is spe-
cifically elevated during cell cycle progression in the
highly proliferating advanced human adenocarcinoma
cell line HT-29 [28,29] is further elevated by IGF-1 but
suppressed by the bioactive compound RSV. Thus, a
specific decrease in the activity of 2 key enzymes
G6PDH and TKT, may lead to suppression of PPP that
provides precursors of nucleotides for cancer cell cycle
progression. Resveratrol at high concentration (150 μM)
showed pronounced suppression of G6PDH and TKT in
the presence of IGF-1. IGF-1 has been shown to elevate
cancer cell proliferation via elevation of ROS (reactive
oxygen species) [39]. At high concentrations where
resveratrol has been shown to be pro-oxidant, the pro-
nounced effect of resveratrol on pentose phosphate
pathway in the presence of IGF-1 may be due to ele-
vated ROS levels that promotes apoptosis [20,44].
Detailed mechanistic reason for this potentiated effect is
still need to be delineated, however, based on our earlier
Figure 3 Effect of RSV (50, 100 and 150 μM denoted as +, ++ and +++ respectively) and/or IGF-1 (10 nM) on G6PDH (A) and TKT (B)
enzyme activities in HT-29 colon cancer cells. HT-29 cells were treated with RSV and/or IGF-1 for 24 h and G6PDH and TKT enzyme activities
were analyzed as described in materials and methods. Results were expressed as means ± SE for three replicate experiments for each treatment
group. Means that differ by a common letter (a, b, c, d, e, f) differ (p < 0.05).
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studies we propose that this might be due to elevated
suppression of pAKT, Cyclin D1, nuclear b-catenin and
SP1, proteins critical for cancer cell proliferation and
cell cycle progression, in the presence of IGF-1 by
resveratrol [6].
Suppression of PPP by RSV may be via inhibition of
mTORC1. Recent evidence has shown clearly that the
mTORC1 controls downstream metabolic pathways like
the PPP via S6K1/SREBP-1/2 [47]. Our earlier
experiments with mTOR signaling revealed that RSV
activated tuberous sclerosis protein 2 (TSC-2, an
mTORC1 inhibitor) and suppressed two best character-
ized downstream targets of mTORC1 (mammalian tar-
get of rapamycin complex 1), p70S6 kinase 1 (S6K1)
and eukaryotic initiation factor 4E (eIF4E) binding pro-
tein 1 (4E-BP1) [48].
Talin-FAK interaction has been well established and is
implicated in various cancers [49,50]. Talin plays an
Figure 4 Map of cytoskeleton remodeling pathway (Genego Metacore, fragment) overlapped with quantile-normalized estimations of
protein abundance. Flags indicate direction of change (red, up-increased, blue; down-decreased) and fold change (length) of protein
abundance in relation to non-treated control. 1, IGF-1 and 2, Resveratrol. Results were expressed as mean for three replicate experiments for
each treatment group.
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essential role in integrin activation and acts as a link
between cell and ECM to regulate cancer cell kinetics
[49]. Talin has been shown to engage in focal adhesion
interactions with Akt signaling as the intracellular survi-
val mechanism to confer anoikis (anchorage indepen-
dent apoptosis) [51,52] resistance and promote cancer
cell invasion, especially in prostate cancer [49]. IGF-1
has been consistently linked to increased cell prolifera-
tion and cell migration, elevating cell invasion and meta-
static properties of cancer cells [53]. Our earlier work
with systems biology to identify biomarkers in meta-
static progression of cancer featured talin as one of the
differentially expressed genes in metastatic tumors in
the context of cytoskeleton remodeling pathway [1].
Even the current proteomics data had talin as one of
the differentially expressed proteins in IGF-1 and RSV
treatments (Figure 4). RSV elevated talin levels at low
concentration (50 μM) and suppressed talin, and con-
currently elevated apoptosis at high concentration (150
μM). This may be due to the action of RSV as an anti-
oxidant at low concentrations and pro-oxidant at high
concentrations [38,44,54]. Anti-oxidant action at lower
doses could protect DNA damage via scavenging of
ROS, whereas at high concentration RSV acts as pro-
oxidant leading to oxidative breakage of cellular DNA in
the presence of transition metal ions such as copper
causing apoptosis [44,54]. This could possibly explain
differences in talin activity at low vs high concentrations
of RSV (RSV at 50 μM is not sufficient to induce apop-
tosis [20]). However, RSV was effective in suppressing
IGF-1 stimulated talin expression, irrespective of con-
centration used. “FAK carries out protein-protein inter-
action adaptor functions at sites of cell attachment to
the extracellular matrix (ECM), thereby contributing to
focal-adhesion ‘scaffolding’. FAK also transmits adhe-
sion-dependent and growth-factor-dependent signals
into the cell interior [50,55].” The synergistic signaling
between growth-factor receptors like IGF-1R and FAK
might be particularly relevant as both are often up-regu-
lated in tumor cells [36,55]. FAK has also been shown
to work similar to the IGF-1R to activate common path-
ways, leading to increased proliferation and cell survival.
Figure 5 Effect of RSV (50, 100 and 150 μM denoted as +, ++ and +++ respectively) and/or IGF-1 (10 nM) on talin and pFAK proteins
in HT-29 colon cancer cells. Western blot analysis was performed as described in materials and methods. b-actin served as a loading control.
Results were expressed as mean ± SE for three replicate experiments for each treatment group. Means that differ by a common letter (a, b, c, d,
e, f) differ (p < 0.05).
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At least in pancreatic cancer, it has been shown that
dual inhibition of FAK and IGF-1R led to a synergistic
decrease in cell proliferation and increase in cell detach-
ment and apoptosis compared with inhibition of either
pathway alone [56,57]. We have shown previously that
RSV inhibits IGF-1R in HT-29 cells [6]. RSV suppressed
FAK activation in the presence and absence of IGF-1.
These results indicate that RSV suppression of cell pro-
liferation and elevation of apoptosis involves modulation
of FAK signaling, considering that the integrin-mediated
FAK signaling regulates both proliferative and apoptotic
signaling pathways [58,59].
Conclusions
Proteomic profiling enabled us to identify novel targets
of RSV. Our results establish PPP and the talin-pFAK as
targets of RSV to suppress cancer cell proliferation and
induce apoptosis in colon cancer cell line HT-29. These
studies may prove germane to the envisaged use of RSV
as a colon cancer chemopreventive agent as well as pro-




RSV and other cell culture materials were obtained from
Sigma Chemical Co. (St. Louis, MO). IGF-1 was pur-
chased from R&D Systems (Minneapolis, MN). Fetal
bovine serum (FBS) was obtained from HyClone
(Thermo Fisher Scientific, Inc., Pittsburgh, PA).
Cell line
Colon cancer cell line HT-29, was obtained from the
American Type Culture Collection (Manassas, VA).
Cells were maintained at 37°C in a humidified atmo-
sphere with 5% CO2 and grown in Dulbecco’s Modified
Eagle’s Medium (DMEM) F-12 supplemented with 10%
fetal bovine serum (FBS), 2.2 g/L sodium bicarbonate,
0.2 g/L bovine serum albumin and 10 mL/L streptomy-
cin-penicillin mix.
Sample preparation
HT-29 cells were seeded at a density of 1.5 × 105 cells/
mL in DMEM F-12 media with 5% charcoal-stripped
FBS. Next day, cells were treated with DMSO (solvent
control), IGF-1 (10 nM) or RSV (150 μM) for 24 h. We
found from dose response studies with IGF-1 (5-20 nM)
that 10 and 20 nM IGF-1 treatments did not differ (p <
0.05) in elevating cell proliferation (data not shown).
Therefore, we used 10 nM concentration of IGF-1 for
our experiments, which is close to normal circulating
levels. Protein was extracted into a high-salt buffer con-
taining 1% protease and phosphatase inhibitor cocktail,
and protein concentrations were determined by a BCA
Protein Assay kit (Pierce, Rockford, IL). The lysate sam-
ples (200 μg) were reduced, alkylated and double
digested with trypsin to generate peptides. The digested
peptides were completely dried in a SpeedVac and sus-
pended in 100 μL of 5% acetonitrile acidified with 0.1%
formic acid (mobile phase A). 200 μg of peptides (40 μl)
were directly loaded onto a 1 × 150 mm Poly-SEA
strong cation exchange column (Michrom Bioresources,
Auburn, CA) using Agilent 1200 auto sampler. Peptides
were eluted to 10 fractions using 0-100 mM ammonium
formate for 40 min (mobile phase B: 1 M ammonium
formate, 10% Formic acid in 5% acetonitrile) and 5 frac-
tions in 100-1000 mM ammonium formate for 10 min
on Agilent 1200 Capillary LC and Analytical-fraction
collector at a flow rate of 50 μL/min. Peptides were
dried and reconstituted in 10 μl of 0.1% TFA for LC-
MS/MS analysis.
HPLC-Chip/MS analysis
A 3 μl volume of peptides (30% of SCX fraction) were
injected into an LC/MS system consisting of an 1100
Series liquid chromatograph, HPLC-Chip Cube MS
interface, and 1100 Series LC/MSD Trap XCT Ultra ion
trap mass spectrometer (all Agilent Technologies, Santa
Clara, CA). The system was equipped with an HPLC-
Chip (Agilent Technologies) that incorporated a 160 nL
enrichment column and a 150 mm × 75 μm analytical
column packed with Zorbax 300SB-C18 5 μm particles.
Peptides were loaded onto the enrichment column with
97% solvent A (water with 0.1% formic acid). They were
then eluted with a gradient from 3% to 45% solvent B
(acetonitrile with 0.1% formic acid) in 25 min, followed
by a steep gradient to 90% solvent B in 5 min at a flow
rate of 0.3 μl/min. The total runtime, including column
reconditioning, was 35 min. The column effluent was
directly coupled to an LC/MSD Trap XCT Ultra ion
trap mass spectrometer from Agilent Technologies via a
HPLC-Chip Cube nanospray source operated at ~1900
volts in ultra-ultra mode. The gain control (ICC) was
set to 500,000 with a maximum accumulation time of
150 milliseconds. Collision induced dissociation (CID)
was triggered on the six most abundant, not singly
charged peptide ions in the m/z range of 450-1500. Pre-
cursors were set in an exclusion list for 1 min after two
MS/MS spectra. Results were expressed as mean for
three replicate experiments for each treatment group.
Data analysis
CID data was searched against the NCBInr human data-
base, using the Agilent Spectrum Mill Server software
(Rev A.03.03.) installed on a HP Intel® Xeon (TM) dual
processor server. Peak lists were created with the Spec-
trum Mill Data Extractor program with the following
attributes: scans with the same precursor ± 1.4 m/z
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were merged within a time frame of ± 15 s. Precursor
ions needed to have a minimum signal to noise value of
25. Charges up to a maximum of 7 were assigned to the
precursor ion, and the 12C peak was determined by the
Data Extractor. The NCBInr database was searched for
tryptic peptides with a mass tolerance of ± 2.5 Da for
the precursor ions and a tolerance of ± 0.7 Da for the
fragment ions. Two missed cleavages were allowed. A
Spectrum Mill auto validation was performed first in the
protein details followed by peptide mode using default
values [Minimum scores, minimum scored peak inten-
sity (SPI), forward minus reversed score threshold, and
rank 1 minus rank 2 score threshold]. All protein hits
found in a distinct database search by Spectrum Mill are
non-redundant.
Data scaling and normalization
Quantitative estimation of differences between physiolo-
gical states by analysis of proteomics data has a number
of challenges. Only a fraction of proteins actually pre-
sent in each sample is identified and a still smaller frac-
tion is quantified. Technical variation overlapped with
these fractions results in substantial differences in the
range of variation for identified fraction even though the
overall range of variation between samples is similar
(see Additional file 1, Figure S1). The resulting distribu-
tion of quantified protein abundance units has long tails
of low-abundance proteins and proteins identified in
only one of the samples. It is commonly advised that for
MS proteomics (unlike microarrays) more technical
replicates should be done in order to control variation
and achieve more reliable quantitative estimation of
change between samples. However, this expensive and
labor-intensive “brute force” approach is not always fea-
sible. We have taken an alternative data analysis
approach which allows quantitative estimation of
changes between samples with limited number of esti-
mates. Our method is based on a reasonable assumption
of little or no change in abundance for the majority of
proteins in all samples. None of the experimental condi-
tions we create in this project can be associated with
lethality or high stress. There is also no indication of
experiment-induced stress response in the pattern of
expressed proteins. Assuming that relatively small frac-
tion of genes have large fold changes we can apply
quantile normalization algorithm, similar to that
described by Bolstad et al. [60] for microarray normali-
zation: xnorm = F
-1(G(x)), where F is the distribution
function of the actual sample, and G is the reference dis-
tribution function. We estimate G by the empirical dis-
tribution of each sample and F by using the empirical
distribution of the averaged quantitative estimations of
peptide abundance in samples across all experimental
conditions, not just replicate groups. This approach has
proven to be effective in low-replicate microarray stu-
dies [1,61]. In our implementation G is more smoothly
estimated by application of additional Savitski-Golay
polynomial smoothing [62]. In addition after scaling, we
zero down scaled values for proteins not identified in
particular sample. Quantile normalization scales all pro-
tein abundances in all samples to the same distribution
and allows realistic estimation of fold change between
experimental conditions.
Biological pathway analysis
All lists of identified proteins and respective normalized
expression values were imported to GeneGo Metacore
(GeneGo INC, St. Josef, MI). Analysis of overrepresenta-
tion of canonical pathways, co-regulation/protein inter-
action pathways and comparative network analyses are
performed using intrinsic tools and pre-formed analysis
pipelines of Genego Metacore.
Western blot analysis
HT-29 cells were seeded at a density of 1.5 × 105 cells/
mL in Dulbecco’s Modified Eagle’s Medium F-12 with
5% charcoal-stripped fetal bovine serum for 24 h. Cells
were treated with solvent control (DMSO), IGF-1 (10
nM), different concentrations of RSV (50, 100 and 150
μM) with and without IGF-1 for 24 h. Protein was
extracted into a high-salt buffer containing 1% protease
inhibitor cocktail from Sigma-Aldrich (St. Louis, MO),
and protein concentrations were determined by a BCA
protein assay kit from Pierce (Rockford, IL). Cell lysates
(45 μg) were incubated at 98°C for 5 min and separated
on 4-12% Criterion XT bis-tris gel at 120 V for 2 h in
1X XT MOPS Running Buffer (Bio-Rad Laboratories,
Hercules, CA) and electrophoretically transferred to
Immuno-Blot PVDF membranes (Bio-Rad) at 95 V for
35 min in tris-glycine transfer buffer with 0.025% SDS.
PVDF membranes were blocked with Superblock buffer
(Thermo Fisher Scientific Inc.) for 1 h at room tempera-
ture. The membranes were incubated with rabbit poly-
clonal anti-pFAK antibody (1:500; Cell Signaling,
Danvers, MA) or mouse monoclonal anti-talin antibody
(1:750; Millipore, Billerica, MA) or goat polyclonal anti-
b-actin antibody (1:2500; Santa Cruz Biotechnology,
Santa Cruz, CA). Membranes were also probed with
respective IgG-HRP secondary antibodies from Santa
Cruz Biotechnology (1:20,000; Santa Cruz, CA) and
scanned using UVP imaging software (UVP BioDoc-It®
Imaging System; Upland, CA). b-actin served as a load-
ing control.
Enzymatic analysis
G6PDH activity was measured using Glucose-6-Phos-
phate Dehydrogenase assay kit (Biovision, Mountain
View, CA). G6PDH activity was measured at absorbance
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450 nm using the manufacturer’s protocol. TKT activity
was determined using the method of de la Haba et al
[63]. Briefly, protein extracts were added to a 96-well
plate containing 216 mM glycylglycine, 3.3 mM xylu-
lose-5-phosphate, 1.7 mM ribose 5-phosphate, 0.002%
(w/v) cocarboxylase, 0.14 mM ß-nicotinamide adenine
dinucleotide (reduced form), 15 mM magnesium chlor-
ide, 20 units a-glycerophosphate dehydrogenase/triose-
phosphate isomerase (based on triosephosphate
isomerase units). Decrease in absorbance was recorded
over 15 minutes at 340 nm and activity was determined
based on the method of de la Haba et al [63]. Protein
concentration of cell extracts was determined using the
BCA protein assay (Pierce) to calculate the specific
activity of the enzymes.
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